Parkinson's Disease Treatment - STALEVO
  Novartis Pharma US

 





Novartis invites you to visit our site devoted to senior health and Medicare Part D.  Click here.

STALEVO Snapshot
STALEVO enhances the benefits of levodopa therapy.

Bullet

Provides increased 'on' and decreased 'off' time

Bullet

Demonstrates rapid and significant improvement in motor function and ADLs

Bullet

Provides more consistent and reliable delivery of levodopa to the brain

Bullet

Blocks both major enzymes that break down levodopa

Bullet

Is available in 3 strengths—each with a 1:4 ratio of carbidopa/levodopa + 200 mg of entacapone

 
o STALEVO 50 (12.5/50/200 mg)
o STALEVO 100 (25/100/200 mg)
o STALEVO 150 (37.5/150/200 mg)

Also in this Section:
E-detail Product Information

Please see Important Safety Information.






Information to help your patients better manage Parkinson's Disease
 Resources
STALEVO Home  |  Professionals Main Page  |  STALEVO Overview
More Information About PD  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.

Novartis proudly supports the Together Rx Access program.
Together Rx Access